Table 1:

Effectiveness and pharmacogenetic contraindications of the 10 highest-grossing drugs [64,103]

Highest Grossing Drugs [64]	Effectiveness	Is there a pharmacogenetic contraindication?	Recommendation [103]
Abilify	1 in 5 people	Yes	CYP2D6 poor metabolizers should have their dose decreased 33%
Nexium	1 in 25 people	Yes	CYP2C19 ultra-metabolizers require a 50–100% increase in dose for the treatment of H. Pylori
Humira	1 in 4 people	Not yet determined	N/A
Crestor	1 in 20 people	Yes	SLC01B1 alterations may affect metabolism
Cymbalta	1 in 9 people	Not yet determined	N/A
Advair Diskus	1 in 20 people	Not yet determined	N/A
Enbrel	1 in 4 people	Not yet determined	N/A
Remicade	1 in 4 people	Not yet determined	N/A
Copaxone	1 in 16 people	Not yet determined	N/A
Neulasta	1 in 13 people	Not yet determined	N/A